Cover Image
市場調查報告書

細菌性感染疾病相關的各種合作契約:契約條件·協定內容

Global Bacterial Partnering 2010-2016: Deal trends, players and financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 246682
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
細菌性感染疾病相關的各種合作契約:契約條件·協定內容 Global Bacterial Partnering 2010-2016: Deal trends, players and financials
出版日期: 2016年09月01日 內容資訊: 英文
簡介

本報告提供的細菌感染性疾病相關的各種合作契約調查分析,提供近幾年的各種契約趨勢,大規模契約及大醫藥品經營者的契約概要,契約類型·開發現階段·疾病區分·各技術區分名錄等彙整資料,為您概述為以下內容。

摘要整理

第1章 簡介

第2章 細菌相關的各種契約趨勢

  • 簡介
  • 過去數年的細菌相關的合作
  • 大製藥公司的契約活動
  • 細菌相關的對產業不積極的大型製藥公司
  • 細菌相關的合作:各類型契約
  • 細菌相關的合作:不同產業市場
  • 細菌相關的合作:各開發階段
  • 細菌相關的合作:各技術類型
  • 細菌相關的合作:細菌的不同症狀
  • 平均契約期間

第3章 主要契約

  • 簡介
  • 主要契約:各交易金額
  • 大型製藥公司有關的主要契約

第4章 大製藥公司的契約

  • 簡介
  • 大製藥公司的合作契約的利用法
  • 合作企業簡介

第5章 合作契約名錄

  • 簡介
  • 各類型契約
  • 各開發階段
  • 各技術類型

第6章 細菌相關的契約:不同症狀

  • 簡介
  • 不同症狀的契約

第7章 合作機會

  • 網路夥伴合作
  • 合作夥伴活動
  • 相關資料

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2206bac

The ‘Global Bacterial Partnering 2010-2016: Deal trends, players and financials’ report provides comprehensive understanding and unprecedented access to the bacterial partnering deals and agreements entered into by the worlds leading healthcare companies

‘Global Bacterial Partnering 2010 to 2016’ provides the full collection of Bacterial disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

  • Trends in Bacterial partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Bacterial partnering agreement structure
  • Bacterial partnering contract documents
  • Top Bacterial deals by value
  • Most active Bacterial dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Bacterial disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Bacterial deals.

The report presents financial deal terms values for Bacterial deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Bacterial dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Bacterial dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Bacterial deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Bacterial dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Bacterial deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Bacterial partnering deals by specific Bacterial target announced since 2010. The chapter is organized by specific Bacterial therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Bacterial partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Bacterial partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Bacterial technologies and products.

Report scope

‘Global Bacterial Partnering 2010 to 2016’ is intended to provide the reader with an in-depth understanding and access to Bacterial trends and structure of deals entered into by leading companies worldwide.

‘Global Bacterial Partnering 2010 to 2016’ includes:

  • Trends in Bacterial dealmaking in the biopharma industry since 2010
  • Analysis of Bacterial deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Bacterial deal contract documents
  • Comprehensive access to over 3500 Bacterial deal records
  • The leading Bacterial deals by value since 2010
  • Most active Bacterial dealmakers since 2010

The report includes deals for the following indications:

Bacterial: Anthrax, Campylobacter Jejuni, Clostridium difficile, Diphtheria, Escherichia Coli (E-coli), Group A Streptococcus, Group B Streptococcus, Haemophilus influenzae type b (Hib), Helicobacter Pylori, Lyme disease, Methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium avium, Pertussis (Whooping Cough), Pseudomonas aeruginosa, Salmonella, Sepsis, Tetanus, Tuberculosis (TB), plus other bacterial indications.

In ‘Global Bacterial Partnering 2010 to 2016’, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Bacterial Partnering 2010 to 2016’ report provides comprehensive access to available deals and contract documents for over 1,000 bacterial deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise bacterial rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Bacterial Partnering 2010 to 2016’ provides the reader with the following key benefits:

  • In-depth understanding of Bacterial deal trends since 2010
  • Access Bacterial deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Bacterial partner companies
  • Comprehensive access to over 750 links to actual Bacterial deals entered into by the world's biopharma companies
  • Indepth review of Bacterial deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Bacterial opportunities
  • Uncover companies actively partnering Bacterial opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Bacterial dealmaking

  • 2.1. Introduction
  • 2.2. Bacterial partnering over the years
  • 2.3. Bacterial partnering by deal type
  • 2.4. Bacterial partnering by industry sector
  • 2.5. Bacterial partnering by stage of development
  • 2.6. Bacterial partnering by technology type
  • 2.7. Bacterial partnering by therapeutic indication

Chapter 3 -Financial deal terms for Bacterial partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Bacterial partnering
  • 3.3. Bacterial partnering headline values
  • 3.4. Bacterial deal upfront payments
  • 3.5. Bacterial deal milestone payments
  • 3.6. Bacterial royalty rates

Chapter 4 - Leading Bacterial deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Bacterial partnering
  • 4.3. List of most active dealmakers in Bacterial
  • 4.4. Top Bacterial deals by value

Chapter 5 - Bacterial contract document directory

  • 5.1. Introduction
  • 5.2. Bacterial partnering deals where contract document available

Chapter 6 - Bacterial dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Bacterial therapeutic target

Appendices

  • Appendix 1 - Directory of Bacterial deals by company A-Z 2010 to 2016
  • Appendix 2 - Directory of Bacterial deals by deal type 2010 to 2016
  • Appendix 3 - Directory of Bacterial deals by stage of development 2010 to 2016
  • Appendix 4 - Directory of Bacterial deals by technology type 2010 to 2016
  • Further reading on dealmaking
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Bacterial partnering since 2010
  • Figure 2: Bacterial partnering by deal type since 2010
  • Figure 3: Bacterial partnering by industry sector since 2010
  • Figure 4: Bacterial partnering by stage of development since 2010
  • Figure 5: Bacterial partnering by technology type since 2010
  • Figure 6: Bacterial partnering by indication since 2010
  • Figure 7: Bacterial deals with a headline value
  • Figure 8: Bacterial deals with upfront payment values
  • Figure 9: Bacterial deals with milestone payment
  • Figure 10: Bacterial deals with royalty rates
  • Figure 11: Active Bacterial dealmaking activity- 2010 to 2016
  • Figure 12: Top Bacterial deals by value since 2010
Back to Top